News >

IMpassion130 Trial Takes Immunotherapy to Forefront of TNBC

Ellie Leick
Published: Monday, Aug 05, 2019

Eleni Andreopoulou, MD, Madeline and Stephen Anbinder Clinical Scholar, Hematology/Oncology, Medicine, associate professor of clinical medicine, Weill Cornell Medicine

Eleni Andreopoulou, MD

Findings from the phase III IMpassion130 trial, which demonstrated that atezolizumab (Tecentriq) combined with nab-paclitaxel (Abraxane) improved progression-free and overall survival (OS) in triple-negative breast cancer (TNBC), are changing standard practice, explained Eleni Andreopoulou, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x